Pivotal phase III COMPOSE trial to compare lutetium (177Lu) edotreotide with best standard of care in patients with well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors

Autor:	Jaume Capdevila, Daniel Halperin, Diane Reidy-Lagunes, Grace Kong, Halfdanarson Thorvardur R, Josh Mailman, Ken Herrmann, Rajaventhan Srirajaskanthan, Thomas Thevenet, Philip Harris
Rok vydání:	2023
Předmět:	General Medicine
Zdroj:	Endocrine Abstracts.
ISSN:	1479-6848
DOI:	10.1530/endoabs.90.p117
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::d62ef854ce349d53d0d0c920ec335ce8 https://doi.org/10.1530/endoabs.90.p117 Zobrazit plný text záznamu